SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin’s proposal to raise FII limit gets CCEA’s nod

29 Jan 2015 Evaluate

The Cabinet Committee on Economic Affairs (CCEA) has approved pharmaceutical major Lupin’s proposal to raise the foreign institutional investment limit to 49% from 33%. With this, the company is expected to attract Rs 6,099 crore.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations as well as biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.

 

Lupin Share Price

2465.00 22.65 (0.93%)
07-May-2026 12:45 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1842.50
Dr. Reddys Lab 1310.35
Cipla 1373.30
Zydus Lifesciences 941.40
Lupin 2465.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×